Barclays raised the firm’s price target on Xencor (XNCR) to $26 from $23 and keeps an Overweight rating on the shares. The firm adjusted price targets in the biotechnology space as part of its 2026 outlook.
Claim 55% Off TipRanks
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Discover top-performing stock ideas and upgrade to a portfolio of market leaders with Smart Investor Picks
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on XNCR:
- Xencor’s New Study on XmAb657: A Potential Game-Changer for Muscle Diseases
- Xencor issued U.S. patent for Xtend Fc domain
- Xencor initiated with a Buy at Truist
- Xencor’s Promising Oncology and Autoimmune Advances Justify Buy Rating with $38 Price Target
- Xencor price target raised to $42 from $40 at Cantor Fitzgerald